TLSs are specialized immune cell aggregates resembling lymph nodes that arise ectopically within tumors or chronically inflamed tissues. Their presence has been strongly correlated with enhanced patient survival and improved responsiveness to immunotherapy regimens, marking them as critical elements of effective antitumor immunity. However, the natural formation of TLSs is neither universal nor well understood, with many tumors demonstrating an immunologically “cold” microenvironment lacking these critical immune niches. The difficulty in replicating TLS formation and function in laboratory models has hampered efforts to study and ultimately harness these structures for therapeutic benefit.

To address this challenge, the Moffitt research team developed a sophisticated injectable hydrogel system composed primarily of chitosan, a biodegradable polysaccharide, integrated with meticulously engineered lipid-coated microparticles. These microparticles are loaded with a cocktail of immune signaling molecules that include chemokines — which recruit specific immune cell subsets — and cytokines — which activate and modulate immune cell behavior. Upon injection beneath the skin in murine models, the hydrogel slowly releases these bioactive factors, creating a chemotactic gradient that draws T cells, B cells, and antigen-presenting cells to the biomaterial interface.

This localized immune cell recruitment subsequently culminates in their self-organization into highly structured clusters that recapitulate critical architectural and functional features of TLSs observed in actual tumor sites. Histological and molecular analyses confirmed that these induced TLS-like structures closely mimic natural tertiary lymphoid organs, displaying segregated T and B cell zones, follicular dendritic cell networks, and germinal center-like areas crucial for adaptive immune responses. Importantly, the presence of these synthetic TLSs correlated with pronounced activation of tumor-specific T cells and significant attenuation of tumor progression in the treated mice.

The ability to engineer TLS formation on demand represents a significant breakthrough, as it not only facilitates detailed mechanistic studies into TLS biology but also offers a translational platform for therapeutic innovation. With many cancers currently lacking pre-existing TLSs and exhibiting resistance to checkpoint inhibitors and other immunotherapies, this approach provides a means to “warm up” cold tumors by constructing their own immune hubs. Enhancing this in situ immune environment could fundamentally change the landscape of cancer treatment by empowering endogenous immune cells to mount robust attacks against malignant cells.

Dr. Rana Falahat, the lead scientist on the project and a research expert in Moffitt’s Immuno-Oncology Program, emphasizes the transformative potential of this biomaterial strategy. She highlights the intersection of biomaterials science and immunology as a fertile ground for novel cancer therapies, noting that the precision release of chemokines and cytokines from the hydrogel sets in motion a highly orchestrated sequence of immune events that were previously difficult to replicate in vivo. This precision enables unprecedented control over TLS generation and function, which could unlock new immune mechanisms and therapeutic targets.

Beyond cancer, the implications of this research may extend to chronic infections and autoimmune diseases, where TLSs are also implicated. Understanding how to trigger or modulate these lymphoid-like structures could lead to treatments that either boost host defense against pathogens or suppress pathological immune activity. However, the immediate focus remains on translating these findings into clinical interventions for cancer patients, particularly those with tumors refractory to current immunotherapies due to the absence of TLSs.

The hydrogel-based approach offers several advantages over conventional methods of immune modulation. Its biodegradability ensures gradual resorption and minimal long-term foreign body effects, while the injectable format provides a minimally invasive means to initiate complex immune microenvironments in situ. The lipid-coated microparticles serve as effective reservoirs for sustained release, maintaining a localized high concentration of immune signals without systemic toxicity. This biomaterial platform demonstrates a refined capacity to emulate natural immune organogenesis ex vivo, bridging the gap between bench and bedside.

Current efforts are underway to further characterize the molecular pathways and cellular interactions underpinning TLS induction by the biomaterial system, aiming to optimize the composition and timing of chemokine and cytokine release. Additionally, researchers are investigating combinatorial approaches pairing the TLS-inducing hydrogel with other immunotherapeutic agents to maximize synergistic antitumor effects. Preclinical studies in more complex tumor models and eventually clinical trials will be critical next steps to evaluate safety, efficacy, and potential for integration into existing cancer treatment paradigms.

The study, published in the Proceedings of the National Academy of Sciences, was supported by prominent funding agencies including the National Cancer Institute and several philanthropic foundations dedicated to cancer research. This collaborative effort underscores the interdisciplinary nature of modern immuno-oncology research, merging materials science, molecular biology, and clinical oncology to innovate transformative therapies. The biomaterial system’s success heralds a new era where engineered immune microenvironments could be tailored to overcome tumor immunosuppression and harness the full power of the body’s defenses.

Ultimately, this research exemplifies a paradigm shift in cancer treatment strategies: moving from broadly acting systemic therapies to precise, localized immune engineering. By providing a scaffold for the body’s immune cells to coordinate their attack within the tumor microenvironment, the TLS-inducing biomaterial promises to convert previously unresponsive cancers into candidates for effective immunotherapeutic intervention. As research progresses, this technology could redefine the approach to cancer immunotherapy and offer hope for patients with hard-to-treat tumor types.

Subject of Research:
Article Title: Chemokine/cytokine-releasing biomaterials induce in situ tertiary lymphoid–like structures and enhance antitumor immunity
News Publication Date: November 6, 2025
Web References: https://www.pnas.org/doi/10.1073/pnas.2409560122
References: Proceedings of the National Academy of Sciences, 3-Nov-2025
Keywords: Immunotherapy, Tertiary lymphoid structures, Biomaterials, Cancer immunology, Hydrogel, Chemokines, Cytokines, Tumor microenvironment

The complexity of NRAS-mutant melanoma lies in its resistance to many existing treatments. Unlike BRAF-mutant melanoma patients, who benefit from diverse FDA-approved targeted therapies, those with NRAS mutations face a dearth of options beyond immune checkpoint inhibitors. Unfortunately, a significant portion of these patients either do not respond to immunotherapies or eventually develop resistance, underscoring the critical need for novel, effective targeted approaches. Daraxonrasib’s development addresses this gap head-on by focussing on RAS proteins locked in their constitutively “on” configuration, a state that perpetuates uncontrolled cellular growth and immune suppression within the tumor microenvironment.

At the molecular level, RAS proteins function as binary switches that regulate key signaling cascades such as the MAPK pathway, which promotes malignant behaviors in cancer cells. Mutations in NRAS result in its persistent activation, circumventing physiological control mechanisms. Daraxonrasib binds specifically to these active RAS forms, disrupting their signal transduction capabilities. This inhibition halts tumor cell proliferation and induces apoptotic cell death, but perhaps even more compelling is the drug’s capacity to modulate the tumor immune microenvironment. Laboratory models revealed that daraxonrasib not only diminishes cancer cell viability but also enhances infiltration by activated T lymphocytes, particularly CD4+ and CD8+ subsets, which are crucial for recognizing and eradicating tumor cells.

Further examination in preclinical settings demonstrated that daraxonrasib’s antitumor effects are heavily reliant on the host immune system. Treatment led to a notable decrease in myeloid-derived suppressor cells, a population of immune cells known to facilitate tumor immune escape. When these suppressive cells were depleted or when T cells were experimentally removed, the efficacy of the RAS inhibitor was significantly diminished or abolished, indicating that daraxonrasib functions synergistically with the immune system. This dual action — direct tumor inhibition and immune activation — enhances the drug’s potential for durable therapeutic responses, a feature that could markedly improve patient outcomes in NRAS-mutant melanoma.

Clinical translation of these findings was marked by the treatment of two patients with advanced NRAS-mutant melanoma in an early-phase trial involving daraxonrasib. Remarkably, one patient experienced a complete response, with no detectable tumor on imaging studies, while the other achieved a substantial partial response. These outcomes are unprecedented in the context of RAS inhibitors for this melanoma subtype, signifying a monumental breakthrough in targeted cancer therapy. Such results underscore not only the drug’s promise but also validate the concept of targeting active RAS proteins as a viable therapeutic strategy.

The journey toward making daraxonrasib widely available, however, remains in its nascent stages. Currently, the drug is undergoing a phase 1 clinical trial designed to evaluate safety, tolerability, and optimal dosing parameters. Success in this initial trial will pave the way for more extensive phase 2 and phase 3 studies, which are essential for definitively assessing efficacy across broader patient populations and diverse clinical settings. These subsequent trials will also probe the drug’s side effect profile and long-term benefits, critical factors for regulatory approval and clinical adoption.

The study highlighting these findings was recently published in the esteemed journal Cancer Immunology Research, emphasizing the scientific community’s recognition of its significance. The research was bolstered by funding from Revolution Medicines and the Melanoma Research Alliance, illustrating the collaborative effort required to drive innovation in oncologic drug development. If daraxonrasib proves successful in larger trials, it could establish the first targeted therapy for NRAS-mutant melanoma, a milestone that has eluded oncology for decades.

Moffitt Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, spearheaded this research with a commitment to advancing cancer treatment modalities. The center’s multidisciplinary approach facilitated the integration of molecular biology, immunology, and clinical oncology, fostering an environment conducive to discovery. Their clinical infrastructure and expertise also enabled the seamless translation of laboratory insights into early human trials, accelerating the pathway from bench to bedside.

The implications of daraxonrasib’s mechanism of action extend beyond NRAS-mutant melanoma. Since it targets the active forms of multiple RAS isoforms, this therapeutic modality holds potential applicability against other RAS-driven malignancies, which constitute a significant fraction of human cancers. Successfully inhibiting RAS has been a “holy grail” in cancer drug development for decades due to the protein’s pivotal role in tumor biology and its notoriously “undruggable” nature. This study, therefore, represents a monumental leap forward in the field of targeted cancer therapies.

In conclusion, the discovery and early clinical validation of daraxonrasib offer new hope for patients with NRAS-mutant melanoma, a subgroup historically lacking effective targeted treatments. By simultaneously disrupting oncogenic RAS signaling and harnessing the immune system’s power, this approach sets a new benchmark in anticancer strategy. Ongoing and future clinical trials will be paramount in confirming these promising results and potentially transforming the therapeutic landscape for this aggressive form of melanoma. The oncology community watches with great anticipation as daraxonrasib progresses through clinical development, holding the promise of a new era in precision oncology.

Subject of Research: People
Article Title: RAS(ON) multi-selective inhibition drives antitumor immunity in preclinical models of NRAS-mutant melanoma
News Publication Date: 4-Nov-2025
Web References: https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066.CIR-25-0744/767109/RAS-ON-multi-selective-inhibition-drives-antitumor
References: Cancer Immunology Research, DOI 10.1158/2326-6066.CIR-25-0744
Keywords: Melanoma, NRAS-mutant melanoma, RAS inhibitor, daraxonrasib, targeted therapy, cancer immunotherapy, tumor microenvironment, precision oncology

The investigation spearheaded by Dr. Rebecca Hesterberg and her team in Moffitt’s Department of Tumor Microenvironment and Metastasis focused on the intricate ways in which B cell lymphoma modulates immune cell function. T cells, a critical subset of immune cells responsible for targeting and eliminating pathogens and malignant cells, were shown to undergo dramatic transformations in the presence of lymphoma. Remarkably, young, healthy T cells began to exhibit molecular and functional features characteristic of aged cells, an effect measured by markers such as chronic inflammation, disrupted proteostasis, and impaired iron homeostasis.

At a molecular level, the study painstakingly mapped out how lymphoma exposure causes T cells to accumulate excess iron, which in turn renders them resistant to ferroptosis—a form of programmed cell death dependent on iron and lipid peroxidation. Ferroptosis resistance enables these dysfunctional T cells to escape normal cellular turnover, potentially leading to permanent immune dysfunction. Alongside iron overload, impaired protein quality control mechanisms were observed, a hallmark phenomenon associated with cellular senescence and organismal aging. These findings constitute compelling evidence that the lymphoma milieu drives a premature aging program within immune cells.

Further examination revealed that the aging effects induced by lymphoma extend well beyond the immune system. The researchers detected hallmark signs of accelerated aging in vital organs such as blood vessels, kidneys, and intestines in animal models. This systemic aging phenotype points to a cancer-driven, body-wide remodeling that likely exacerbates the frailty and comorbidities often observed in lymphoma patients. The dismantling of tissue homeostasis in multiple organs presents a concerning picture of cancer as a disruptor of overall organismal integrity and metabolic health.

Importantly, this study challenges the long-standing dogma that the accelerated aging commonly seen in cancer patients primarily arises as a side effect of toxic therapies such as chemotherapy and radiation. While these treatments do cause cellular damage and functional decline, the researchers demonstrated that the lymphoma itself can independently instigate immune and tissue aging. This uncoupling of cancer-related aging from treatment effects pushes the scientific community to reconsider how we assess and manage survivorship and long-term health in lymphoma patients.

Dr. John Cleveland, Ph.D., Chief Scientific Officer at Moffitt and senior author of the study, emphasized the clinical significance of these findings, stating, “Cancer doesn’t exist in isolation; it modifies the patient’s entire biological landscape. Our data show that lymphoma alone is sufficient to trigger systemic aging markers, explaining why many patients experience age-related symptoms irrespective of treatment.” This understanding paves the way for more nuanced therapeutic approaches that target not only cancer cells but also the broader physiological disruptions caused by the disease.

One of the most promising revelations from the research is that many of the aging-like changes instigated by lymphoma are not irreversible. Experimental models demonstrated that removing tumors resulted in the partial rescue of immune and tissue function, suggesting that these aging processes can be therapeutically modulated. This raises exciting possibilities for developing adjunct treatments aimed at restoring healthy cellular function and mitigating premature aging symptoms in lymphoma patients.

The study leveraged cutting-edge observational methodologies to analyze immune cells and tissue samples from both human subjects and animal models. Using multi-omics profiling—including transcriptomics, proteomics, and metabolomics—the team delineated the complex network of biological pathways perturbed by lymphoma. Chronic inflammation, or “inflammaging,” emerged as a central driver of the observed phenotypes, linking tumor presence with systemic immune activation and cellular decline. Such integrated systems biology approaches are critical for unraveling the multifaceted impact of cancer on the host.

On a broader scale, these discoveries invite reflection on the intersection of cancer biology and gerontology. With global populations aging rapidly and cancer incidence rising exponentially with age, understanding how tumors accelerate tissue senescence may inform preventative strategies and improve patient quality of life. The reciprocal relationship between aging and cancer initiation and progression becomes more evident, underscoring the need for research at this interface.

The financial and institutional support behind this effort—from the National Institutes of Health to collaborative organizations such as the Leukemia and Lymphoma Society and the Florida Department of Health—highlights the importance of multidisciplinary funding in tackling complex biomedical challenges. This study exemplifies how sustained investment in translational research yields insights with broad implications for public health.

Looking ahead, the team advocates for deeper mechanistic studies to identify specific molecular targets within the lymphoma-driven aging axis. Therapeutics designed to modulate iron metabolism, enhance proteostasis, or quell chronic inflammation could revolutionize cancer treatment paradigms. Addressing the systemic effects of lymphoma offers a dual benefit: more effective oncologic control and healthier survivorship, free from the debilitating consequences of premature aging.

In conclusion, the revelation that lymphoma accelerates T cell and tissue aging marks a transformative stride in cancer biology. It reframes tumors as active agents of systemic physiological remodeling rather than localized proliferative anomalies alone. This new understanding demands integration into clinical management and inspires hope for innovative therapies that safeguard immune function and organ vitality during and after cancer.

Subject of Research: People
Article Title: Lymphoma accelerates T cell and tissue aging
News Publication Date: August 21, 2025
Web References:

• https://www.moffitt.org/
• https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/
• https://www.sciencedirect.com/science/article/pii/S1535610825003290
  References:
• DOI: 10.1016/j.ccell.2025.07.023
  Keywords: T lymphocytes, lymphoma, immune aging, ferroptosis resistance, iron metabolism, proteostasis, inflammaging, tissue senescence

The study, recently published in the prestigious journal Nature, provides robust evidence that the interaction between cancer cells and tumor-associated nerves plays a significant role in shaping the tumor microenvironment. Specifically, the cancerous cells infiltrate and degrade the protective myelin sheath surrounding these nerves. Damage to the nerve fibers leads to the release of inflammatory mediators such as interleukin-6 (IL-6) and type 1 interferons, which initially may trigger tissue repair mechanisms but eventually contribute to creating an immunosuppressive milieu that blunts anti-tumor immune responses.

Anti-PD-1 immunotherapy, which has revolutionized treatment for several cancers by unleashing T-cell mediated immune attack on malignant cells, faces a significant clinical challenge: many patients do not respond or develop resistance over time. The findings of this study shine a light on a previously unappreciated resistance pathway—nerve injury-induced inflammation—that actively suppresses immune activity within the tumor. By altering nerve integrity, tumors can effectively modulate immune surveillance and escape eradication.

Kenneth Tsai, M.D., Ph.D., co-corresponding author and co-director of the Donald A. Adam Melanoma and Skin Cancer Center of Excellence at Moffitt Cancer Center, stated that their team’s findings emphasize the direct influence of nerve injury on immune cell behavior within tumors. “Our research illustrates that nerve injury is not simply collateral damage from tumor growth, but rather a functional driver that remodels the immune landscape, facilitating immune evasion. The exciting part of our work is demonstrating that this process is reversible, opening the door to potential interventions,” Dr. Tsai explained.

Utilizing patient-derived samples and preclinical models encompassing a variety of cancer types—including cutaneous squamous cell carcinoma, melanoma, gastric cancer, and pancreatic cancer—the research team dissected the cellular dynamics at play. They observed that nerve damage induced by cancer cells triggers a complex inflammatory response, which, although initially reparative, transitions into a chronic suppressive state that dampens immune cell infiltration and activation.

To intervene in this detrimental feedback loop, the researchers explored multiple therapeutic strategies designed to restore immune sensitivity. They discovered that resistance to anti-PD-1 therapy could be mitigated by either surgically removing pain-transmitting nerves, pharmacologically blocking neuronal injury signaling pathways, or employing combination therapies that target both the PD-1 axis and the IL-6-mediated inflammatory pathways. These approaches successfully reversed tumor-induced immune resistance in preclinical settings, underscoring their translational potential.

This research highlights a critical and previously underexplored role for the nervous system in cancer progression and therapeutic resistance. Traditionally, oncology has focused primarily on the direct interactions between cancer cells and immune cells, but this study underscores that nerve-cancer cross talk can profoundly shape immunological outcomes. Targeting nerve injury-related signals could, therefore, become an innovative strategy to enhance responses to current immunotherapies.

Moreover, the study lays groundwork for future investigations into the molecular mechanisms by which nerve damage alters immune signaling within the tumor microenvironment. Key inflammatory mediators like IL-6 and type 1 interferons may become biomarkers for identifying patients likely to exhibit resistance due to nerve involvement. This stratification could guide personalized treatment regimens incorporating nerve-targeted therapies.

Clinically, targeting nerve injury pathways has compelling implications, especially for cancers characterized by perineural invasion—a phenomenon where tumors grow along nerves, commonly linked to poor prognosis and reduced treatment efficacy. By neutralizing the immune-suppressive signaling that arises from nerve damage, oncologists may improve therapeutic outcomes and extend patient survival.

Dr. Tsai further emphasized, “Understanding the bidirectional crosstalk between nerves and cancer cells reveals new vulnerabilities we can exploit therapeutically. Our discovery encourages an integrative perspective that combines neural biology and immunology to combat tumor immune evasion.”

The study was rigorously funded by the National Institutes of Health, underscoring its significance and potential impact on cancer research and treatment paradigms. As nerve-targeted therapy development advances, combination treatments involving immune checkpoint inhibitors and nerve injury signaling blockers could enter clinical trials, offering hope to patients who currently face limited options due to immune resistance.

In conclusion, this pioneering work broadens the conceptual framework of tumor immunology by incorporating the nervous system as a key player in cancer progression and resistance mechanisms. It challenges existing paradigms and paves the way for innovative, multi-modal treatment strategies that could transform patient outcomes in the era of precision oncology.

Subject of Research: People

Article Title: Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy

News Publication Date: 20-Aug-2025

Web References:
https://www.nature.com/articles/s41586-025-09370-8

References:
Tsai, K., et al. (2025). Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature. DOI: 10.1038/s41586-025-09370-8

Keywords: Immunotherapy

TIL therapy, an avant-garde form of cellular immunotherapy, harnesses the body’s own immune cells to combat cancer. The process involves surgically excising a patient’s tumor, from which highly potent immune cells called lymphocytes are isolated. These TILs, having naturally infiltrated the tumor site, are expanded ex vivo to tremendous numbers before being reintroduced into the patient’s bloodstream to intensify the anti-cancer immune response. Although this treatment has delivered remarkable clinical responses in several cancers, its success in NSCLC has been inconsistent.

The Moffitt research team meticulously analyzed tumor and immune cell samples from a cohort of NSCLC patients previously enrolled in a TIL therapy clinical trial. Their comparative approach involved distinguishing biological differences between those who exhibited favorable responses and those who did not. A key observation was that in non-responders, the infused TILs failed to persist or remain functionally active over time. This lack of sustained T cell survival undermines the therapeutic impact, effectively allowing the cancer to regain a foothold.

Beyond T cell persistence, the investigation uncovered phenomena related to tumor antigen dynamics. Tumor antigens are molecular flags present on cancer cells that enable immune cells to recognize and target malignancies. Surprisingly, in patients unresponsive to TIL therapy, certain neoantigens—the mutated proteins that are pivotal for immune recognition—showed a marked decline or even complete loss as treatment progressed. This antigenic attrition presents a formidable evasion mechanism by the tumor, granting it stealth against immune detection and attack.

Dr. Chao Wang, Ph.D., a clinical science researcher at Moffitt and co-author of the study, elaborated on these findings by emphasizing the multifactorial nature of resistance: “Our in-depth exploration has revealed that both the temporal depletion of effective T cells and the tumor’s ability to shed critical antigens converge to thwart TIL therapy efficacy. These dual challenges must be addressed to push the boundaries of therapeutic success.”

Subsequent analyses highlighted that patients durable to therapy maintained a pool of TILs capable of surviving and proliferating within the host environment, thereby continuously exerting anti-tumor activity. In contrast, non-responders demonstrated rapid decline in T cell viability and function post-infusion, which correlated closely with disease progression. The loss of immunologically targetable neoantigens further exacerbated this failure, suggesting that tumor evolution under immune pressure leads to a form of adaptive resistance.

From these insights, experts like Dr. Ben Creelan, M.D., a medical oncologist at Moffitt’s Thoracic Oncology Department and co-author, emphasized the imperative to innovate therapeutic approaches. “Enhancing the longevity and functional fitness of T cells post-infusion, alongside strategies to stabilize or reintroduce key tumor antigens, may be the linchpin for improving patient outcomes,” he noted. The future may well involve integrating gene-editing technologies to engineer more robust TILs that resist exhaustion and evade tumor-induced suppression.

Moreover, the potential to manipulate tumor antigenic landscapes opens exciting prospects. Gene-editing or molecular interventions could restore or mimic lost neoantigens, preventing tumors from escaping immune surveillance. By maintaining a consistent portfolio of recognizable targets, TIL therapies could sustain their cytotoxic activity, leading to more durable clinical remissions.

To accelerate progress in this domain, the Moffitt team has made their sequencing data and research materials publicly accessible via National Institutes of Health archives. This act of scientific generosity is aimed at fostering global collaboration, enabling other researchers to build upon their findings and explore combinatorial treatment modalities that could overcome identified resistance mechanisms.

The implications of this study are profound, highlighting the dynamic interplay between immune cell persistence and tumor evolutionary strategies. It underscores the need for a holistic approach in immunotherapy development—one that simultaneously addresses T cell survival, antigen stability, and tumor microenvironment modulation. These insights could steer future clinical trial designs toward combination therapies pairing TIL infusion with agents that bolster immune cell metabolism or restore antigen expression.

As TIL therapy continues to mature, integrating advances such as next-generation sequencing, single-cell profiling, and molecular engineering will be paramount. This multi-angled approach ensures that personalized immunotherapy regimens become increasingly precise, tailored not just to tumor type but to the individual’s tumor and immune system dynamics over the course of treatment.

Ultimately, overcoming the dual hurdles of T cell attrition and neoantigen loss could transform TIL therapy from a niche treatment into a frontline weapon in the fight against metastatic NSCLC. This breakthrough represents a pivotal step toward turning what has been experimental promise into widespread clinical reality, potentially changing the prognosis for thousands of lung cancer patients worldwide.

The Moffitt Cancer Center stands at the forefront of this evolving frontier, combining immunological expertise with translational research to push the boundaries of cancer therapy. By continuing to dissect the underlying biology of immune resistance, researchers aspire to develop next-generation therapies that deliver sustained remission and improved quality of life for patients battling advanced lung cancer.

Subject of Research: People

Article Title: Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy

News Publication Date: 8-May-2025

Web References:

• Moffitt Cancer Center: https://moffitt.org/
• Nature Cancer Article DOI: http://dx.doi.org/10.1038/s43018-025-00946-x
• TIL Therapy Overview at Moffitt: https://www.moffitt.org/treatments/immunotherapy/til-therapy/

References:
Wang C., Creelan B., et al. (2025). Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy. Nature Cancer. DOI: 10.1038/s43018-025-00946-x

Keywords: Immunotherapy, Tumor-Infiltrating Lymphocytes, Lung Cancer, Non-Small Cell Lung Cancer, T Cell Persistence, Neoantigen Loss, Tumor Immune Evasion, Cellular Immunotherapy, Cancer Resistance Mechanisms

TIL therapy is an innovative form of immunotherapy that begins with oncologists excising tumors from patients. Following surgical removal, these tumors are transported to specialized laboratories where researchers dissect them to collect immune cells that have infiltrated the cancerous tissue. These tumor-infiltrating lymphocytes, or TILs, are then cultivated in controlled environments, expanding their numbers significantly before being reinfused back into the patient’s bloodstream. The goal is that these reinfused TILs will specifically target and eliminate remaining cancer cells.

While TIL therapy is currently FDA-approved for the treatment of melanoma, the Moffitt research team has discovered that by introducing CD40L into the culture medium of TILs, they can significantly enhance both the quantity and quality of the cancer-fighting TILs. Dr. Daniel Abate-Daga, the scientific director of Moffitt’s Cell Therapies Core, explained this breakthrough by likening the addition of CD40L to “flipping a switch” that fortifies and revitalizes these immune cells, enabling them to mount a more robust attack against tumors.

The results of the study indicate that the incorporation of CD40L led to a marked improvement in TIL growth rates. In challenging specimens, TIL cultures grew successfully in 67% of samples treated with CD40L, whereas only 33% of samples without CD40L exhibited similar results. Moreover, this revolutionary methodology not only enhances cell proliferation but also significantly reduces the manufacturing time for TIL therapy, potentially expediting treatment administration to patients. By shortening the process by as much as one week, the enhanced TIL therapy can be made available to patients in need more swiftly.

Furthermore, researchers observed that the TILs expanded using CD40L exhibited more "stem-like" characteristics, a crucial factor that correlates with their ability to maintain anti-cancer effects for a more extended period. The implications of these findings are immense; TIL therapy, which is already considered one of the most effective treatments for solid tumors, stands to benefit significantly from this new approach, allowing more patients to access potentially life-saving treatments more rapidly.

Emphasizing the frank potential of these findings, Dr. Abate-Daga indicated that this discovery could help more patients benefit from TIL therapy and do so more quickly and effectively. He conveyed optimism for the next generation of TIL therapy, which may include treatments not only for melanoma but also for a wider variety of cancers. Currently, Moffitt Cancer Center is leading a clinical trial to investigate the application of CD40L-enhanced TILs in patients suffering from non-small cell lung cancer, a prevalent and often challenging form of cancer.

This innovative research has garnered support from esteemed funding bodies, including the National Cancer Institute, the SuzyQ Melanoma Fund, Moffitt’s Lung Cancer Center of Excellence, and various other organizations focused on cancer research and treatment advancements. The exploration of CD40L signals a notable evolution in the field of immunotherapy, marking a pivotal step toward optimizing TIL therapy for a broader swath of cancer patients who stand to benefit.

As the study unfolds, greater clarity will emerge regarding not just the efficacy of CD40L-enhanced TILs but also their potential safety profiles and long-term benefits in patients undergoing therapy. The Moffitt Cancer Center’s commitment to pushing the boundaries of cancer research continues to bear fruit, as experts aim to unravel the complexities of the immune response to solid tumors and refine therapeutic strategies aimed at leveraging these responses.

Overall, the advancements made in this research underscore the critical synergy between immune cell activation and the development of tailored immunotherapies. The integration of CD40L represents a convergence of years of scientific inquiry and leads to novel treatment modalities that could transform patient outcomes in cancer care. With each discovery, the intricate interplay between cancer cells and the immune system offers new insights and hope for those battling this formidable disease.

Researchers, clinicians, and patients alike will be watching closely as the findings of this study are translated into clinical practice, potentially reshaping the landscape of cancer treatment and enhancing the lives of countless individuals affected by various forms of cancer. The ability to modify TIL therapy through the addition of immune signaling proteins like CD40L stands testament to the innovative spirit that drives advancements in cancer research.

Importantly, the future of immunotherapy may rely heavily on such integrative approaches, cultivating a landscape where the body becomes a formidable ally against the disease it faces, reshaping our understanding of how to combat cancer from within.

Subject of Research:
People

Article Title:
CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

News Publication Date:
August 4, 2025

Web References:
Journal for Immunotherapy of Cancer
National Cancer Institute

References:
10.1136/jitc-2024-011066

Image Credits:
Moffitt Cancer Center

Keywords:
Cell therapies, immunotherapy, cancer treatment, tumor-infiltrating lymphocytes, CD40L, non-small cell lung cancer, melanoma.

The research indicates that blocking MARCO alters the behavior of immune cells within the tumor microenvironment. This alteration results in an increased influx of immune cells, which subsequently augments the effectiveness of anti-CTLA4 treatments. This development is particularly significant for what are termed "cold" tumors—cancers that typically lack sufficient immune cell presence and often prove resistant to conventional immunotherapies. The findings suggest that targeting MARCO can help mobilize the immune system in a way that was previously unattainable for many patients suffering from these challenging tumor types.

James Mulé, who serves as the associate center director for Translational Science at Moffitt and leads the study, articulated the research’s implications by noting that targeting MARCO could bolster the efficacy of existing immunotherapeutic drugs without necessitating the depletion of macrophages. This finding not only introduces a new paradigm for treating melanoma but also lays the groundwork for broader application in various types of cancers, providing hope to those in need of innovative treatment options.

Investigators performed an experimental study utilizing animal models, wherein they introduced a monoclonal antibody aimed at MARCO, observing its effects when combined with anti-CTLA4 therapy. The results were striking: the combination treatment led to a substantial increase in immune cell infiltration within the tumor. Dendritic cells, which are instrumental in priming the immune response against tumors, showed particular enhancement in their numbers following the combination therapy, highlighting the synergistic potential of this new approach.

It is intriguing to note that this study specifically mentioned that similar improvements were not observed when anti-MARCO therapy was paired with anti-PD1 treatment. This distinction underscores the unique role MARCO plays in enhancing anti-CTLA4 efficacy. The researchers emphasize the necessity of further dissecting the underlying mechanisms at play to better understand the immunological dynamics following MARCO inhibition.

Furthermore, the study opens doors for clinical trials aimed at integrating MARCO-targeting strategies into both neoadjuvant and adjuvant therapy settings. By mitigating the chances of cancer recurrence through enhanced immune preparation within the tumor microenvironment, the findings could significantly reshape our approach to cancer prevention and treatment.

Publications such as these have essential implications not only for melanoma treatment but also for a multiplicity of cancers where current therapies fall short. This research underlines the importance of continual innovation in cancer treatment modalities, striving to provide more comprehensive care to patients.

The significance of this study cannot be overstated, as it brings to light the intricate interplay between immune cells and tumor cells and emphasizes the need for tailored therapies that resonate with the biology of the disease. As Moffitt Cancer Center continues to push the envelope in cancer research, this study represents a vital stepping stone toward more effective and personalized treatment options for patients battling cancer.

In conclusion, the targeting of MARCO presents a promising avenue for enhancing the efficacy of immunotherapy for melanoma and potentially other cancers. The implications of this research are profound, suggesting that a redefined approach to immuno-oncology could lead to substantial improvements in patient outcomes. These findings herald an exciting future in cancer therapy, where personalized medicine and innovative strategies converge for better patient care.

Subject of Research: Animals
Article Title: Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming
News Publication Date: March 13, 2025
Web References: Moffitt Cancer Center
References: Journal for ImmunoTherapy of Cancer
Image Credits: None provided
Keywords: Immunotherapy, melanoma, MARCO, anti-CTLA4, cancer research, immune cells, tumor microenvironment, clinical trials, personalized medicine.

The findings of the study are particularly significant as they disclose that CD4+ Th1 cells exhibit a specialized immune response that can identify and eliminate dormant cancer cells within the body. These cells often hide from traditional treatments, permitting them to re-emerge years after initial therapies have effectively eradicated visible tumors. The research team, led by Brian Czerniecki, MD, PhD, chair of the Breast Oncology Department, discovered that the presence of cytokines, particularly IFN-γ, could force these dormant cells into a non-proliferative state, preventing their growth and the possibility of new tumor formation. This revelation could indeed be a “game-changer” in the realm of cancer prevention, offering hope for long-term cancer management.

Interestingly, the study goes beyond merely identifying immune cell activity; it probes the underlying biological mechanisms that empower CD4+ Th1 cells to combat cancer. By emphasizing the role of cholesterol biosynthesis in the survival and spread of these dormant cells, researchers suggest that existing pharmaceutical options targeting this pathway might enhance current treatment protocols. Cholesterol has long been implicated in various cellular processes, including proliferation, and the Moffitt team’s findings may lay the groundwork for combining cholesterol-lowering agents with immunotherapy to produce synergistic effects against cancer.

Moreover, the researchers performed a retrospective analysis on the clinical data of breast cancer patients. This analysis indicated a strong correlation: patients with elevated levels of CD4+ Th1 cells exhibited a substantially reduced risk of cancer recurrence. This observation reinforces the hypothesis that enhancing immune responses could serve as a strong adjunct to existing cancer therapies, thereby improving patient prognoses.

The implications of this study extend beyond just breast cancer; they hint at a broader applicability for immune-based approaches in treating various cancers, including melanoma and lung cancer. The mechanisms by which the immune system targets and neutralizes dormant cancer cells may be similarly effective when tailored for different tumor types. Consequently, a deeper understanding of these immune interactions is vital to developing innovative treatment protocols that can improve overall survival rates across the oncology spectrum.

As it stands, the findings prompt a sense of urgency for further research to elucidate how the immune response can be effectively amplified in patients diagnosed with cancer. Future clinical trials aim to explore the potential explosion of effectiveness when combining established immunotherapy strategies with cholesterol-regulating treatments. Such investigations could pave the way for extensive therapeutic regimens that prevent the resurgence of cancer cells and enhance long-term survivorship.

The study also emphasizes the critical importance of ongoing investigations into the biology of cancer dormancy and immunity. As researchers endeavor to unlock the mechanisms that underpin these complex interactions, it becomes increasingly clear that the potential for innovative cancer therapies lies at the intersection of immunotherapy and traditional treatment methods. Capturing the intricacies of immune responses and leveraging them against cancer could usher in a new era of advanced treatment options, ultimately transforming patient care.

In summary, this groundbreaking research conducted at Moffitt Cancer Center articulates the invaluable role that immune responses play in combating dormant cancer cells. Understanding how CD4+ Th1 cells can be mobilized and their metabolic needs addressed could lead to significant breakthroughs in preventing cancer recurrence. As the study open doors to new avenues for therapeutic intervention, the quest continues for ways to harness the immune system’s natural capabilities to fight one of humanity’s most formidable adversaries—cancer.

As the landscape of cancer treatment evolves, the potential for integrating immune-based strategies with conventional approaches is an exciting frontier that holds promise for millions of patients. With the historic recognition of the Moffitt Cancer Center’s commitment to scientific excellence and pioneering cancer research, the study embodies a significant leap toward understanding and mitigating cancer. The integration of innovative techniques and synergistic therapies could ultimately enhance patient care, offer new hope for recovery, and reduce the haunting specter of cancer recurrence that countless individuals face.

The future of cancer treatment will undoubtedly hinge upon the discoveries and strategies arising from research like this, underpinned by collaboration, innovation, and an unyielding quest for a cure.

Subject of Research: Animals
Article Title: Antitumor CD4+ T helper 1 cells target and control the outgrowth of disseminated cancer cells
News Publication Date: 17-Feb-2025
Web References: Moffitt Cancer Center, Cancer Immunology Research
References: DOI 10.1158/2326-6066.CIR-24-0630
Image Credits: N/A

Keywords: Breast cancer, CD4+ T helper cells, Immunotherapy, Cancer recurrence, Cholesterol biosynthesis, Cytokines, Dormant cancer cells

Cancer survivorship presents multiple challenges, from dealing with the physical limitations imposed by treatment to navigating social dynamics that have altered during the medical journey. Research underscores the vital role that regular physical activity plays in alleviating these challenges; it can significantly reduce fatigue, enhance cardiovascular health, and promote weight management. Nevertheless, a staggering 53% to 83% of cancer survivors fail to meet the prescribed levels of physical activity, revealing a critical gap in post-treatment care.

The pilot study, conducted between September 2023 and January 2024, involved a total of 23 participants, comprising 18 cancer survivors and five friends or family members who did not have a cancer history. The focus was on offering an accessible, enjoyable means of engaging in physical exercise while fostering social connections among participants. Notably, the majority of the cancer survivors were women aged 47 to 76, representing a diverse array of cancer types, including breast and hematological cancers.

From the outset, the recruitment phase for Project Rally proved successful, with an impressive 95.5% of the cancer-survivor participants and 77.8% of their companions expressing enthusiasm for the program. Such high engagement rates illustrate a profound interest in community-driven health initiatives, particularly those that incorporate a sense of camaraderie alongside physical activity. Retention rates bolstered these findings further, as 85.7% of cancer survivors completed the entire program, surpassing the predefined goal of 75%.

Physical fitness is a multifaceted endeavor, often encompassing a blend of endurance, strength, and flexibility. The results from Project Rally were uplifting, as participants reported a notable increase in their weekly physical activity levels. Cancer survivors, in particular, displayed over 80 minutes of added moderate-to-strenuous exercise per week, predominantly involving more vigorous activities than they had previously engaged in. The positive effects went beyond mere statistics, as participants also reported elevated feelings of companionship, attributing their enhanced social connections to shared experiences while playing pickleball.

The significant correlation between physical activity and improved well-being extends into various aspects of participants’ lives. Members of Project Rally experienced marked improvements in their strength, endurance, and overall fitness levels. In addition to the physical benefits, the social components of the program—primarily group interactions and learning pickleball techniques together—fostered a new sense of community among participants. Many identified forming new friendships and reinforcing social networks as key advantages of their involvement in the program.

Such findings are pivotal in chronicling the intersection of recreational activities and holistic health care. Nathan Parker, Ph.D., a lead researcher associated with the study, asserts that the implications of Project Rally extend beyond enjoyment. The empirical evidence gathered signals that pickleball can stand as an influential method for enhancing the emotional and physical health of cancer survivors. Parker emphasized the importance of community-based initiatives in giving survivors a platform to remain active, establish connections, and improve their life quality post-cancer treatment.

The enthusiasm surrounding Project Rally has already sparked discussions about future expansion. The program’s design, leveraging the sociable and dynamic nature of pickleball, puts it in a prime position to reach a larger audience, undoubtedly benefiting countless more cancer survivors. As research attests, community-focused programs hold immense promise for facilitating improved health outcomes among vulnerable populations, particularly those grappling with the repercussions of cancer treatment.

Expanding the program further will not only involve reaching out to more cancer survivors but also taking a closer look at refining the sessions and the activities offered. Future sessions may vary in structure and content to accommodate diverse needs, ensuring a tailored approach that aligns with participants’ unique journeys after cancer.

The pilot study has garnered meaningful attention in scientific circles, with its findings published in the esteemed journal Healthcare. The potential for further research could lead to a substantial shift in how wellness programs are tailored to better serve cancer survivors. While Project Rally has already demonstrated several positive outcomes, its trajectory is set to influence health care approaches holistically, advocating for more initiatives that marry fitness and social support systems.

Funding from the Moffitt Cancer Center Office of Community Outreach, Engagement, and Equity has fueled this initiative. Such financial backing not only underscores the importance of community engagement in health research but reaffirms the commitment to elevating cancer survivorship practices through innovative programs. As the domino effect of one survivor positively impacting another kicks in, the ambitions of Project Rally resonate, carrying a message of hope and empowerment for all.

With a strong commitment to growth and inclusivity, Project Rally aims to broaden its coastal reach through additional locations and sessions while proving that getting active and forming social connections form a powerful antidote to the post-cancer landscape. As awareness of the importance of physical health and social bonds continues to rise, there’s no doubt that Project Rally stands at the forefront of redefining cancer survivorship.

In summary, Project Rally’s achievements illuminate a path forward—a future where the physical and emotional needs of cancer survivors are prioritized, community-driven physical activity receives the spotlight it deserves, and pickleball emerges not merely as a sport, but as a vessel for healing and connection within the cancer survivor community.

Subject of Research: People
Article Title: Feasibility, Acceptability, and Outcomes of Project Rally: Pilot Study of a YMCA-Based Pickleball Program for Cancer Survivors
News Publication Date: 28-Jan-2025
Web References: Moffitt Cancer Center, YMCA of the Suncoast
References: Healthcare Journal
Image Credits: Moffitt Cancer Center

Keywords: Cancer Survivorship, Physical Activity, Community Programs, Pickleball, Health and Wellness

The study, which is elegantly encapsulated in the article titled “Intricacies of human–AI interaction in dynamic decision-making for precision oncology,” published in the prestigious journal Nature Communications, focuses specifically on AI-assisted radiotherapy. Radiotherapy is among the most commonly deployed cancer treatments, utilizing high-energy radiation to target and obliterate malignant tumors. The researchers investigated a novel approach termed knowledge-based response-adaptive radiotherapy (KBR-ART). This innovative method leverages AI algorithms to enhance therapeutic outcomes by recommending real-time treatment adjustments influenced by the patient’s responses.

In their comprehensive evaluation, the researchers found compelling evidence that the application of AI in adjudicating treatment plans fosters greater consistency among physicians. By employing AI-driven models to propose alterations in radiation doses based on extensive patient data—including imaging and diagnostic results—doctors exhibited reduced variability in treatment decisions. Such standardization is particularly crucial in oncology, where inconsistencies can lead to disparate patient outcomes.

Nonetheless, the study also illuminated a key finding: while AI serves as a valuable ally, it does not necessarily supersede the clinical acumen of oncologists. In various instances, physicians chose to diverge from AI recommendations, citing their clinical judgment and individual patient considerations as paramount. This behavior underlines a crucial aspect of cancer care—each patient presents a unique profile defined by multifaceted factors that data-driven algorithms may not fully encapsulate.

During their investigation, clinical practitioners were tasked with making treatment choices for patients, first independently and subsequently with AI assistance. The AI framework utilized in this study proactively analyzed patient data to suggest adjustments in treatment protocols based on feedback concerning treatment efficacy. Although many oncologists embraced AI recommendations as beneficial, a notable subset preferred to rely on their professional intuition, underscoring the potent role of human expertise in the decision-making continuum.

Dr. Issam El Naqa, a leading figure in the study and chair of the Machine Learning Department at Moffitt, poignantly remarked on the fundamental interplay between AI analytics and human judgment in the oncology sphere. He emphasized that while AI provides powerful insights derived from intricate datasets, the quintessential human touch cannot be overlooked. Ultimately, cancer patients are not mere data points; they are individuals with unique histories requiring tailored therapeutic strategies.

The findings of this research extend beyond immediate clinical application. They underscore the necessity for building trust between clinicians and AI systems. The researchers demonstrated that physicians are more inclined to adhere to AI-generated recommendations when they possess confidence in its validity and reliability. Such trust is imperative for ensuring the constructive integration of AI within clinical practice. This relationship between clinicians and AI is not predicated on the displacement of one by the other, but instead hinges on the harmonious coexistence of human expertise and technological advancement.

Moreover, the implications of the study are profound. The authors advocate for the harmonious amalgamation of AI tools within everyday clinical workflows, aspiring to foster collaborative partnerships that enhance the personalization of treatment regimens offered to cancer patients. This study signifies a commendable leap forward; moving towards a healthcare paradigm wherein AI serves as a supportive backbone that fortifies clinical decisions rather than undermining the expertise and intuition of medical professionals.

In pursuit of future advancements, the research team plans to assess how AI can optimize decision-making across various medical fields. The need for interdisciplinary collaboration and knowledge transfer between fields is as paramount as ever. This endeavor may unveil new methodologies and strategies for harnessing AI’s capabilities in personalized medicine, thereby amplifying its advantages across a broader spectrum of healthcare concerns.

The study received substantial backing from the National Institutes of Health, particularly through grant R01-CA233487. This financial support underscores the critical need for comprehensive research in a landscape where technology and medicine converge, emphasizing that innovative approaches are essential to drive progress in cancer treatment.

As artificial intelligence continues to permeate various sectors of healthcare, the findings from this study serve as an invaluable framework for navigating the evolving landscape, highlighting the practicality and nuances of integrating AI into complex medical environments. The results signify a promising horizon for precision oncology and pave the way for a better understanding of how technological advancements can complement the efforts of healthcare professionals in addressing patients’ needs.

The research featured in this study stands at the cusp of multiple disciplines, from computer science to oncology, thereby allowing for a multifaceted exploration of its findings. Future exploration of the intricate interactions between human clinicians and AI systems will be pivotal in determining how best to harness these technologies for improved patient outcomes.

In conclusion, while this research points to a future where AI can significantly enhance cancer treatment pathways, it also serves as a reminder of the irreplaceable value of human intuition and expertise in navigating the complexities of patient care. As we continue to delve into the symbiotic relationship between machine learning and medicine, the journey towards optimizing clinical practices remains an exciting frontier.

Subject of Research: Cancer treatment decision-making using AI in precision oncology.
Article Title: Intricacies of human–AI interaction in dynamic decision-making for precision oncology.
News Publication Date: 30-Jan-2025.
Web References: Moffitt Cancer Center
References: DOI: 10.1038/s41467-024-55259-x
Image Credits: N/A

Keywords: Artificial intelligence, oncology, cancer treatment, radiotherapy, human-AI collaboration, precision medicine, decision-making, clinical research, machine learning.